Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 1.2023. Journal of the National Comprehensive Cancer Network : JNCCN Moses, K. A., Sprenkle, P. C., Bahler, C., Box, G., Carlsson, S. V., Catalona, W. J., Dahl, D. M., Dall'Era, M., Davis, J. W., Drake, B. F., Epstein, J. I., Etzioni, R. B., Farrington, T. A., Garraway, I. P., Jarrard, D., Kauffman, E., Kaye, D., Kibel, A. S., LaGrange, C. A., Maroni, P., Ponsky, L., Reys, B., Salami, S. S., Sanchez, A., Seibert, T. M., Shaneyfelt, T. M., Smaldone, M. C., Sonn, G., Tyson, M. D., Vapiwala, N., Wake, R., Washington, S., Yu, A., Yuh, B., Berardi, R. A., Freedman-Cass, D. A. 2023; 21 (3): 236-246

Abstract

The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease.

View details for DOI 10.6004/jnccn.2023.0014

View details for PubMedID 36898362